MedDataX Logo

Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment

NCT ID: NCT01428531

Last Updated: 2015-07-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this post-marketing surveillance study is to collect and assess information on safety and efficacy of fondaparinux injection in patients with venous thromboembolism (VTE).

("Arixtra" is a trademark of the GlaxoSmithKline group of companies.)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)

NCT01428544

Ataxia
COMPLETED

Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection

NCT01420809

Thromboembolism
COMPLETED

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

NCT00443053

Thrombosis, Venous
COMPLETED PHASE3

Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)

NCT01390883

Cardiovascular Disease
COMPLETED

ARIXTRA® Adherence in SVT Patients.

NCT01691495

Thrombosis, Venous
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ataxia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients prescribed fondaparinux

Fondaparinux Sodium

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fondaparinux Sodium

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with acute pulmonary thromboembolism or acute deep venous thrombosis
* Fondaparinux injection must be prescribed for the first time

Exclusion Criteria

* Not applicable
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

115489

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients
NCT00521885 TERMINATED NA
Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery
NCT01390896 COMPLETED
Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication
NCT00424281 UNKNOWN
Hemorrhage Risk Prescribed Arixtra
NCT01064362 COMPLETED
Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy
NCT00539942 TERMINATED PHASE3
Arixtra PE Study- Outpatient Management of Stable Acute Pulmonary Embolism: Once Daily Subcutaneous Fondaparinux
NCT00378027 WITHDRAWN
Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism
NCT00413504 COMPLETED NA
The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients
NCT00531843 COMPLETED PHASE2/PHASE3
Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers
NCT00436787 COMPLETED PHASE2
Secondary Prevention of Venous Thrombo Embolism (VTE).
NCT00329238 COMPLETED PHASE3
A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients
NCT02213978 COMPLETED
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
NCT00790335 COMPLETED PHASE3
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
NCT01583218 COMPLETED PHASE3
Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis (PREDICTORS)
NCT02297373 COMPLETED
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
NCT04168203 COMPLETED PHASE4
Fondaparinux in Critically Ill Patients With Renal Failure
NCT01467583 COMPLETED PHASE4
Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
NCT00291330 COMPLETED PHASE3
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
NCT00633893 COMPLETED PHASE3
A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment
NCT03812835 WITHDRAWN
Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and/or Postpartum for Prophylaxis or Treatment of Venous Thromboembolism
NCT01004939 COMPLETED
Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients
NCT02412982 COMPLETED PHASE4
Evaluation of Chemical Venous Thromboembolism Prophylaxis in Trauma
NCT06025162 UNKNOWN
Treatment Patterns Among Patients With Venous Thromboembolism in the United States
NCT05795062 COMPLETED
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
NCT05794165 ENROLLING_BY_INVITATION PHASE2
Comparative Effectiveness and Safety Between Warfarin and Dabigatran
NCT03254134 COMPLETED